Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Naltrexone for Metastatic Melanoma, Prostate, and Renal Cancer
NCT01650350Phase 2Terminated
- Sponsor
- Brown University
- Start
- Nov 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naltrexone in melanoma, prostate cancer (PCa) and renal cell carcinoma (RCC), sponsored by Brown University. Primary endpoint: Number of Responses via RECIST up to 6 months. Started Nov 2012; status: terminated.
02
Drugs
naltrexone
03
Conditions
melanomaprostate cancer (PCa)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01650350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01650350.